3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Sarcoma
1
Histiocytoma, Malignant Fibrous
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
3
Cisplatin
3
Irinotecan
2
Fluorouracil
2
Capecitabine
2
tremelimumab
1
pamiparib
1
durvalumab
1
brigimadlin
1
atezolizumab
1
Temozolomide
1
Surgical Procedures, Operative
1
Paclitaxel
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
IMC-001
1
Blood Specimen Collection
1
ARX788
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Biliary Tract Neoplasms
×
brigimadlin
×
Clear all
NCT06084689
2025-09-02
EMPIRE
Institut Bergonié
Phase 2
Withdrawn